Spero Therapeutics (SPRO) Revenue (2016 - 2026)

Spero Therapeutics (SPRO) has reported Revenue for 11 consecutive years, with $258000.0 the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Revenue fell 95.61% year-over-year to $258000.0; the trailing twelve-month figure through Jun 2026 stood at $47.0 million (down 3.25% YoY), and the FY2025 full-year result was $66.8 million, up 39.24% from the prior year.
• Revenue declined to $258000.0 in Q1 2026 per SPRO's latest filing, from $41.3 million in the prior quarter.
• Across five years, Revenue topped out at $73.5 million in Q4 2023 and bottomed at $258000.0 in Q1 2026.
• Historically, Revenue has averaged $16.0 million across 5 years, with a median of $9.3 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Revenue soared 1628.9% in 2022, then sank 95.61% in 2026.
• Over 5 years, Revenue stood at $47.4 million in 2022, then jumped by 54.98% to $73.5 million in 2023, then tumbled by 79.54% to $15.0 million in 2024, then jumped by 174.51% to $41.3 million in 2025, then sank by 99.38% to $258000.0 in 2026.
• According to Business Quant data, Revenue over the past three periods registered $258000.0, $41.3 million, and $5.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.